The Role of Statins in the Management of Delirium: Recent Advances

Author(s): Junhui Chen, Yuhai Wang, Ximin Hu, Mingchang Li, Kun Xiong, Zhaocai Zhang*, Qianxue Chen*

Journal Name: CNS & Neurological Disorders - Drug Targets
Formerly Current Drug Targets - CNS & Neurological Disorders

Volume 20 , Issue 3 , 2021

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Delirium is a clinical syndrome characterized by a temporary organic mental disorder, as well as abnormal attention and cognition. It is a very common, serious, and costly disease with high misdiagnosis and death/disability rates, especially for older patients after surgery. Several factors, such as systemic neuroinflammation, neurotransmitters, cerebral hypoperfusion and microthrombosis, contribute to the progress of delirium; however, the exact pathophysiologic mechanisms are not well known. Therefore, there are no specific therapeutic approaches that can treat delirium effectively. Statins, as inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, have been identified as potential medications for the treatment of delirium because they can significantly reduce the incidence of delirium. The major objective of the current review is to summarize recent advances in the understanding of the effects and mechanisms of statins on delirium. In basic research, statins can alleviate delirium via attenuation of neuroinflammation, neurotransmitters, cerebral hypoperfusion, and microthrombosis, which may highlight their potential clinical application for the treatment of delirium. Despite this, the clinical effects of statins still provoke debate.

Keywords: Delirium, statins, systemic neuroinflammation, neurotransmitters, cerebral hypoperfusion, microthrombosis, pathophysiological events, inflammation.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 20 July, 2020
Page: [203 - 215]
Pages: 13
DOI: 10.2174/1871527319666200720111318
Price: $65

Article Metrics

PDF: 131